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Introduction:  Microbiologically  derived  cyclodextrin  glucanotransferase  (CGTase)  is  used commercially
as  a processing  agent  in  manufacture  of food,  pharmaceuticals,  and cosmetics.  Its  toxic  potential  was
evaluated  in  anticipation  of  use  in  the production  of  alpha-glycosyl  isoquercitrin,  a  water-soluble  form
of quercetin.
Methods:  Following  OECD  guidelines,  CGTase,  produced  by Bacillus  pseudalcaliphilus  DK-1139,  was  eval-
uated  in a genotoxicity  battery  consisting  of  a bacterial  reverse  mutation  assay,  an  in vitro  micronucleus
(MN)  assay  and  MN  and comet  assays  using  B6C3F1  male  and  female  mice.  These  same  genotoxicity  assays
were also  conducted  for sodium  sulfate,  a  contaminant  of CGTase  preparation.  In a 90-day  Sprague  Daw-
ley rat  toxicity  study,  CGTase  was  administered  by  gavage  in  water  at daily  doses  of  0,  250,  500,  and
1000  mg/kg/day.
Results:  CGTase  did  not induce  mutations  with  or without  metabolic  activation  in the  bacterial  reverse
mutation  assay.  Formation  of micronuclei  was  not  induced  in  either  in  vitro  or in  vivo  MN  assays  with
or  without  metabolic  activation.  No  induction  of  DNA  damage  was  detected  in male  or female  mouselavonol
odium sulfate
liver,  stomach,  or duodenum  in the  comet  assay.  Sodium  sulfate  also  tested  negative  in these  same
genotoxicity  assays.  In the  90-day  repeated  dose  rat  study  there  were  no  treatment-related  adverse
clinical  or pathological  ﬁndings.
Conclusion:  The  genotoxicity  assays  and  repeated  dose  toxicity  study  support  the  safe  use  of CGTase  in
production  of alpha-glycosyl  isoquercitrin.
© 2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Introduction
Cyclodextrin glucanotransferase (CGTase) is one of several
tarch-hydrolyzing extracellular enzymes produced by many bac-
eria to convert large molecules to utilizable small molecules for
rowth. CGTase, a member of the alpha-amylase superfamily, cat-
lyzes cleavage of glycosidic bonds between carbohydrates and/or
on-carbohydrate moieties. As an amylolytic enzyme, CGTase is
Abbreviations: CGTase, cyclodextrin glucanotransferase; EMIQ, enzymatically
odiﬁed isoquercitrin; MN,  micronuclei; MN-RET, micronucleated reticulocytes; M
-NCE, micronucleated normochromatic erythrocytes; GLP, good laboratory prac-
ice; NOAEL, no observed adverse effect level; OECD, Organization for Economic
o-operation and Development; EFSA, European Food Safety Authority.
∗ Corresponding author.
E-mail addresses: maronpot@me.com (R.R. Maronpot), chobbs@ils-inc.com
C.A. Hobbs), jdavis@ils-inc.com (J. Davis), cswartz@ils-inc.com (C. Swartz),
ollyhopevet@gmail.com (M.  Boyle), mihoko-koyanagi@saneigenfﬁ.co.jp
M.  Koyanagi), afbou408@oct.zaq.ne.jp (S.-m. Hayashi).
ttp://dx.doi.org/10.1016/j.toxrep.2016.03.002
214-7500/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
used commercially in manufacture of food, pharmaceuticals, and
cosmetics [10,25]. Our interest is in use of CGTase in synthe-
sis of glycosylated molecules such as alpha-glycosyl isoquercitrin
(EMIQ). CGTase catalyzes addition of one or more glucose units to
isoquercitrin to produce EMIQ (Fig. 1); during processing, this step
is followed by heat inactivation of the CGTase. Even though not
present in the ﬁnal product, food enzymes are subject to safety eval-
uation according to EFSA and current Japanese regulations [6,7].
In the present study we provide a safety evaluation of CGTase,
produced by Bacillus pseudalcaliphilus DK-1139, using a battery of
genotoxicity assays and a 90-day repeated dose toxicity study in
Sprague Dawley rats.
2. Methods2.1. Chemical analysis
All genotoxicity assays were conducted according to OECD
guidelines and were Good Laboratory Practice (GLP)-compliant.
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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Big. 1. CGTase modiﬁes isoquercitrin with dextrin to form alpha-glycosyl iso-
uercitrin.
amples removed from the top, middle, and bottom fractions of
ach chemical formulation were submitted for analytical testing
Alera Laboratories, LLC, Durham, North Carolina, USA). Most ana-
yzed formulation concentrations were greater than 15% of the
ominal dose or were within the ±15% acceptance criteria. The few
ormulations that were lower than 15% of the nominal dose were
ow or mid-range doses that were not used as benchmark doses
o determine overall assay responses. CGTase (Composition = 85%
arbohydrate, 0.3% protein, 0.7% lipid, 12.1% water, 0.26% sodium
ulfate, ≤2 ppm lead, ≤0.5 ppm arsenic, and 1.0% total organic
olvent; CAS No. 9030-09-5; San-Ei Gen F.F.I., Inc., Osaka, Japan)
as prepared in sterile deionized water and stored between 0
nd −30 ◦C and away from light. The neat test article was deter-
ined to be stable, based on enzyme titer, for a period of three
onths with storage at approximately −15 ◦C. Continued stabil-
ty is inferred from repeated formulation analyses in which the
ormulation concentrations, calculated from enzyme activity mea-
urements, routinely exceeded nominal concentrations [1]. Sodium
ulfate (99.7% pure; Tomita Pharmaceutical Co., Ltd., Tokushima,
apan) prepared in sterile deionized water and stored at 1–10 ◦C
nd away from light is stable for at least 8 days [1]. Sodium sulfate,
resent at low levels in preparations of CGTase, was  also tested in
he genotoxicity battery.
.2. Bacterial reverse mutation assay
GLP mutagenicity assays of CGTase and sodium sulfate, with
nd without metabolic activation, were conducted as described
reviously [2,13,14] using the following ﬁve Salmonella and
. coli strains as prescribed in the guideline for the bacte-
ial reverse mutation assay [15]: TA98, TA100, TA97a, TA1535,
nd E. coli WP2  uvrA pKM101. All strains (Moltox, Inc., Boone,
C) were checked for maintenance of genetic markers prior to
he study. Nominal concentrations of CGTase ranged from 25
o 5000 g/plate. Concentrations of sodium sulfate ranged from
50 to 5000 g/plate. Metabolic activation was provided using
henobarbital/benzoﬂavone-induced rat liver S9 (Moltox, Inc.,
oone, NC) with cofactors (RegensysTM NADPH Regeneration Sys-Reports 3 (2016) 381–392
tem Reagents, Moltox, Inc., Boone, North Carolina, USA). The
composition of the S9 mix  was: 10% S9, 8 mM MgCl2, 32.6 mM  KCl,
4.7 mM glucose-6-phosphate, 4 mM NADP, and 0.1 M phosphate
buffer. Cytotoxicity was  assessed by changes in the background
bacterial lawn (i.e., enhanced or absent lawn), reduced revertant
counts, presence of microcolonies, and/or absence of colonies.
Strain speciﬁc positive controls tested without metabolic activa-
tion were 2-nitroﬂuorene, 3 g (TA98), sodium azide, 1 g (TA100
and TA1535), ICR191, 0.25 g (TA97a), and 4-nitroquinoline-N-
oxide, 0.25 g (E. coli WP2). Benzo[a]pyrene, 2 g (TA100) and
2-aminoanthracene, 2 g (TA98); 2.5 g (TA97a, TA1535); 20 g
(E. coli WP2) were used as the positive controls with metabolic
activation. Following a preliminary incubation at 37 ◦C for 20 min
prior to plating, three test plates per concentration were incu-
bated at 37 ◦C for 48 h and then counted using the Sorcerer/Ames
Study Manager System (Perceptive Instruments, Ltd., Suffolk, UK).
To ensure accuracy of the results, reagent sterility and automated
scoring checks were conducted. Criteria for a positive response
were a ≥ 2-fold increase in the average plate count compared to
the solvent control for at least one concentration level and a dose
response over the range of tested concentrations in at least one
strain with or without metabolic activation. In addition, the aver-
age response should fall outside the laboratory historical vehicle
control range for the strain/metabolic activation condition.
2.3. In vitro micronucleus (MN) assay
The GLP in vitro MN assay was conducted in compliance with
OECD TG 487 [18]. Human TK6 cells (ATCC, Manassas, VA) were cul-
tured and maintained in RPMI 1640 medium containing 10% heat
inactivated horse serum plus 1.0% Pluronic F-68, 0.5% sodium pyru-
vate, and antibiotics (penicillin at 20 Units/mL and streptomycin at
20 g/mL) at 37 ◦C, with 6% CO2. The normal cell cycle time of these
cells is approximately 12 h. Metabolic activation was  provided
using phenobarbital/benzoﬂavone-induced rat liver S9 (Moltox,
Boone, NC) with added RegensysTM cofactors (Moltox, Boone, NC) at
a ﬁnal concentration of 1% S9. The composition of the S9 mix  was:
10% S9, 8 mM MgCl2, 32.6 mM KCl, 4.7 mM glucose-6-phosphate,
4 mM NADP, and 0.1 M phosphate buffer. Triplicate cultures of
exponentially growing cells seeded at 0.40 × 106 cells/mL in 12-
well plates were exposed to CGTase, sodium sulfate, or controls for
approximately four hours in the presence of metabolic activation
(+S9) and approximately 24–29 h in the absence of metabolic acti-
vation (-S9). Cyclophosphamide (Sigma-Aldrich, St. Louis, MO)  and
vinblastine (Sigma-Aldrich, St. Louis, MO)  were used as the positive
controls with and without metabolic activation, respectively. On
the basis of preliminary tests, the concentrations of CGTase selected
for testing were 6000, 5000, 4000, 3000, 2000, and 1000 g/mL of
CGTase for approximately 4 h with S9 and 24 h without S9. Concen-
trations of sodium sulfate selected were 5000, 1667, 556, 185, 61.7,
and 20.6 g/mL for 4 h with S9 and 24 h without S9. At the end of the
culture period, cells were analyzed for cytotoxicity and micronu-
cleus induction by ﬂow cytometry using the In Vitro MicroFlowTM
kit (Litron Laboratories, Rochester, NY) according to manufacturer’s
instructions. Unless limited by cytotoxicity, 20,000 cells from each
sample were analyzed for the frequency of micronuclei (MN) using
a FACSCaliburTM dual-laser bench top system (Becton Dickinson
Biosciences, San Jose, CA).
Cytotoxicity was  measured as relative increase in cell count or
as relative survival of cells in vehicle control cultures compared to
cells in treated cultures using ratios of counted nuclei to counted
beads (inert latex microspheres added to each sample). Higher
nuclei to bead ratios correspond to greater cell survival. Greater
emphasis was placed on relative survival since this ﬂow cytometry-
based measurement may  provide a more sensitive assessment of
cytotoxicity, enhancing assay speciﬁcity Avlasevich et al., 2011.
ology 
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s recommended by OECD test guideline #487 [18], concentra-
ions inducing greater than 60% cytotoxicity were excluded from
he analysis. An increase in MN frequency ≥3-fold over the mean
N frequency in the concurrent vehicle control was  considered a
ositive response.
.4. Animal husbandry
For the combined in vivo MN  and comet assays male and female
6C3F1 mice (Charles River Laboratories International, Inc., Raleigh,
C) were 8–10 weeks of age at the time of treatment. Animals
ere housed in polycarbonate cages with absorbent hardwood
edding in an AAALAC-accredited speciﬁc pathogen free facility
ith a 12 h light/12 h dark cycle. Certiﬁed Purina Pico Chow No.
002 (Ralston Purina Co., St. Louis, MO)  and water were provided ad
ibitum. For the 90-day toxicity study male and female Hsd:Sprague
awley rats (Harlan Laboratories, Inc., Frederick, MD)  were housed
ne per cage in polycarbonate cages with heat-treated hardwood
edding (Northeastern Products Corp., Warrensburg, NY) and fed
urina Certiﬁed 5002 Meal Diet (Ralston Purina Co., St. Louis, MO)
d libitum.  These studies were approved by the ILS, Inc. Institu-
ional Animal Care and Use Committee, and all procedures were
ompleted in compliance with the Animal Welfare Act Regulations,
CFR 1–4, and the Guide for the Care and Use of Laboratory Animals
Institute of Laboratory Animal Resources, 2011).
.5. In vivo MN/Comet assay experimental design
GLP studies were conducted in compliance with OECD TG 474
19] and in general accordance with OECD TG 489 [20]. Dose range
nding studies were conducted to identify appropriate dose levels.
ale and female mice were administered CGTase or sodium sulfate
ia oral gavage up to and including dose levels of 2000 mg/kg/day
test guideline limit dose) for three consecutive days. No marked
hanges in body weights were measured nor adverse clinical obser-
ations found in mice administered either chemical and there were
o abnormal gross necropsy organ observations. Therefore, for the
eﬁnitive studies, male and female B6C3F1 mice (5 animals/dose
roup) were administered CGTase or sodium sulfate at 1000, 1500,
r 2000 mg/kg/day, vehicle (deionized water), or the positive con-
rol compound, ethyl methanesulfonate (EMS) (Sigma-Aldrich, St.
ouis, MO)  in 0.9% saline (Ricca Chemical Company, Arlington, TX)
t 150 mg/kg/day, daily for three days by oral gavage. Three hours
fter the ﬁnal dose, peripheral blood was collected for ﬂow cyto-
etric analysis of MN,  and liver, duodenum, and stomach tissues
ere collected, frozen in liquid nitrogen, and stored at -80 ◦C until
nalysis by the comet assay [24].
.6. Erythrocyte micronucleus assay
Peripheral blood samples were processed for ﬂow cytometric
valuation of micronucleated reticulocytes (MN-RET) as described
reviously [26]. Brieﬂy, cells were ﬁxed and labeled using a
icroFlowPLUS Kit (Litron Laboratories, Rochester, NY) according to
anufacturer’s directions and analyzed using a FACSCalibur ﬂow
ytometer (Becton Dickinson, Sunnyvale, CA). For each periph-
ral blood sample, 20,000 RET were analyzed to determine the
requency of MN-RET. More than 106 mature normochromatic ery-
hrocytes were enumerated concurrently during MN-RET analysis,
nd the percentage of RET (%RET) among total erythrocytes was
alculated as a measure of bone marrow toxicity..7. Comet assay
For each animal, a portion of the left lobe of the liver was  placed
nto a tube containing cold mincing solution [Mg++ and Ca++ freeReports 3 (2016) 381–392 383
Hank’s Balanced Salt Solution (Invitrogen, Carlsbad, CA) containing
10% v/v dimethylsulfoxide (DMSO), and 20 mM disodium ethylene-
diaminetetraacetic acid (Na2EDTA) pH 7.4–7.7] and rapidly minced.
A portion of the duodenum proximal to the stomach was removed,
ﬂushed with mincing solution, and kept cold and moist with minc-
ing solution. The tissue was  trimmed and a small section placed
in a microcentrifuge tube containing mincing solution and rapidly
minced. The stomach was cut open and washed free from food
using cold mincing buffer. The glandular stomach was placed into
cold mincing buffer and incubated on ice for 15–30 min, then the
surface epithelium was gently scraped two times using a scalpel
blade. This layer was  discarded and the gastric mucosa rinsed with
cold mincing buffer. The stomach epithelium was  carefully scraped
4–5 times in mincing solution with a scalpel blade to release the
cells. The mincing solution containing released epithelial cells was
transferred to microfuge tubes. Tissue samples were ﬂash frozen
in liquid nitrogen and stored at −80 ◦C until processed [24]. Addi-
tional portions of each tissue were ﬁxed in 10% neutral buffered
formalin (NBF) for at least 24 h, trimmed, and parafﬁn embedded
for possible histopathology assessment of cytotoxicity in the case
of a positive response in the comet assay.
For processing, cells were partially thawed in a warm water
bath and placed on ice until slide preparation. Cell samples were
empirically diluted with 0.5% low melting point agarose (Lonza,
Walkersville, MD)  dissolved in Dulbecco’s phosphate buffer (Ca++,
Mg++ and phenol free) at 37 ◦C, layered onto each well of a 2-
well CometSlideTM (Trevigen, Gaithersburg, MD), and immersed
in cold lysing solution (2.5 M NaCl, 100 mM  Na2EDTA, 10 mM
Tris, pH 10, containing freshly added 10% DMSO and 1% Triton
X–100) overnight. After rinsing in 0.4 M Trizma base (pH 7.5), slides
were treated with alkali (300 mM NaOH, 1 mM Na2EDTA, pH > 13)
for 20 min, then electrophoresed at 4 ◦C for 20 min  at ∼1.0 V/cm,
300 mA.  After electrophoresis, slides were neutralized with 0.4 M
Trizma base (pH 7.5) for 5 min, incubated for 5 min  in ice-cold 100%
ethanol (Pharmco-AAPER, Shelbyville, KY) and allowed to air-dry.
Slides were stored at room temperature in a desiccator until stained
and scored. After staining slides with SYBR GoldTM (Molecular
Probes, Invitrogen, Carlsbad, CA), 100 cells were scored per sam-
ple at 200x magniﬁcation without knowledge of sample identity
using Comet Assay IV Imaging Software¸ Version 4.3.1 (Perceptive
Instruments, Ltd., Suffolk, UK). The extent of DNA migration was
characterized using the% tail DNA endpoint measurement (inten-
sity of all tail pixels divided by the total intensity of all pixels
in the comet, expressed as a percentage). NaCl, Na2EDTA, Triton
X-100, and Trizma base were purchased from Sigma-Aldrich (St.
Louis, MO); NaOH and DMSO were purchased from Fisher Scientiﬁc
(Pittsburgh, PA).
2.8. 90-day repeat dose toxicity study
This GLP-compliant 90-day rat study was conducted following
OECD TG 408 [17]. Ten males and ten females were allocated to each
of four designated dose groups. The animals were administered
one of three dose levels (250, 500, or 1000 mg/kg/day) of CGTase or
deionized water for 90 days via oral gavage. Cage-side observations
were performed daily and body weight measurements and clinical
observations performed weekly. Ophthalmological examinations
were performed prior to exposure to CGTase and again within a
week of termination. Following 11 weeks of exposure, neurotox-
icity screening was performed including measurement of motor
activity and a functional observation battery as deﬁned in OECD TG
424 [16].After 90 days of CGTase administration, animals were humanely
euthanized. Prior to termination, urine was  collected and sub-
mitted for analysis. A full screen necropsy was  performed and
tissue weights were collected for adrenals, brain, epididymides,
3 ology 
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eart, kidneys, liver, lungs, ovaries, pituitary, prostate, salivary
lands, seminal vesicles, spleen, testes, thymus, thyroids with
arathyroids and uterus with cervix. The following tissues were
xed in 10% NBF (with the exception of eyes and testes that
ere ﬁxed in modiﬁed Davidson’s ﬁxative), embedded in paraf-
n, sectioned, and microscopically evaluated: adrenals, aorta, bone
sternum and femur), bone/bone marrow (sternum and femur),
rain (cerebrum, cerebellum, and medulla/pons), cecum and colon,
orpus and cervix uteri, epididymides, esophagus, eyes, heart, kid-
eys, liver, intestines (small and large including Peyer’s patches),
ungs (with main-stem bronchi), lymph nodes (mesenteric and
andibular), mammary glands, muscle (skeletal), nasal cavity,
varies, oviducts, pancreas, pituitary, prostate, salivary glands, sci-
tic nerve, seminal vesicles, skin, spinal cord (3 locations: cervical,
id-thoracic, lumbar), spleen, stomach, testes, thymus (thymic
egion), thyroids/parathyroid(s), tongue, trachea, uterus, urinary
ladder, vagina, Zymbal’s glands. Blood, collected by vena cava
uncture immediately following termination, was submitted for
ematology, clinical chemistry, and hormone determinations (See
ables 5–7 for lists of measurements).
.9. Statistical analyses
For the in vivo MN/comet assay, body weight, MN-RET and
ET frequency data, and DNA damage data were analyzed using
tatistical Analysis System version 9.2 (SAS Institute, Cary, NC).
omogeneity of the data was assessed using the Levene’s test
ith a 95% conﬁdence level. Data were then analyzed using a
ne-way analysis of variance (ANOVA) and treated groups com-
ared to the appropriate control group using Dunnett’s test.
ose-dependent changes were evaluated using linear regression.
ata that were not homogeneous and normally distributed were
nalyzed using the appropriate non-parametric one-tailed Dunn’s
est. Dose-dependent changes were evaluated using an appropriate
on-parametric trend test (Jonckheere’s test). For all in vivo end-
oints, a one-tailed t-test was used to verify a positive response to
he reference compound EMS  (p < 0.05). Criteria for a positive result
n the MN  and comet assays were at least one statistically signif-
cant dose group (p < 0.05), a dose group falling outside the range
f laboratory historical control data, and a statistically signiﬁcant
rend test (p < 0.05). A test was considered equivocal if only one or
wo of these conditions were met  [18,19].
Endpoints in the functional observation battery using inter-
al scales were evaluated for homogeneity using Levene’s test.
 non-signiﬁcant result (p > 0.001) indicated that an assumption
f homogeneity of variance was appropriate, and the data were
ompared using an ANOVA test with groups administered CGTase
ompared to the vehicle control group using Dunnett’s test. If
evene’s test was signiﬁcant (p ≤ 0.001), the ANOVA test was not
ppropriate and the Kruskal-Wallis test was used to analyze the
ata; in the event of a signiﬁcant result (p ≤ 0.05), Dunn’s test was
sed to compare the groups administered CGTase with the con-
rol group. Endpoints in the functional observation battery using
raded or count scales were analyzed using a non-parametric strat-
gy. When 75% or fewer of the scores in all the groups were tied,
he Kruskal-Wallis test was used to analyze the data; in the event
f a signiﬁcant result (p ≤ 0.05), Dunn’s test was used to compare
he CGTase groups with the control group. When more than 75%
f the scores in any group were tied, Fisher’s Exact test was used
o compare the proportion of ties in the groups. Endpoints in the
unctional observation battery using descriptive or quantal scales
ere analyzed using the Fisher’s Exact test.
Data from the motor activity test, with repeated measurements
ithin a session, were analyzed using an ANOVA with Repeated
easures. A signiﬁcant effect (p ≤ 0.05) in that test can appear as
ffect of dose (a difference between groups in the total across allReports 3 (2016) 381–392
measurements in a session) or as an interaction between dose and
time (a difference between groups at speciﬁc measurement peri-
ods).
3. Results
3.1. Results of the bacterial reverse mutation assays
Mutagenicity assays were conducted to assess the potential
of CGTase and sodium sulfate to induce gene mutations in bac-
teria using the pre-incubation method. CGTase caused bacterial
overgrowth at several doses in all strains tested. Precipitate was
observed in all assay tubes and decreased with decreasing dose
of test article, but the precipitate did not interfere with automatic
plate counting. CGTase was not cytotoxic and was  not mutagenic
at analyzable doses in any strain used, either without or with
metabolic activation. Therefore, CGTase is considered to be neg-
ative for mutagenicity in the bacterial reverse mutagenicity assay
under the conditions tested.
Sodium sulfate was  not cytotoxic, did not precipitate, and was
not mutagenic in any strain used, either without or with metabolic
activation. Therefore, sodium sulfate is considered negative for
mutagenicity in the bacterial reverse mutagenicity assay under the
conditions tested. Average plate counts for each set of replicate
plates for both CGTase and sodium sulfate are provided in Table 1.
3.2. Results of the in vitro MN assays
MN are identiﬁed by ﬂow cytometry using a combination of
characteristics of size (as measured by light scatter) and ﬂuores-
cence (based on differential staining) that differentiates debris and
necrotic and apoptotic cells from healthy cells containing micronu-
clei [3,5]. CGTase was slightly cytotoxic to cultured TK6 cells at
concentrations of approximately 4000 g/mL and greater ±S9;
however, cytotoxicity at all tested concentrations was less than
50%. Precipitation was observed at all tested doses. No pH changes
were noted based on media color change. Because the induction
of micronuclei was  less than 3-fold higher than the vehicle control
at all doses both with and without S9, the overall response was
considered negative. These data indicate that, under the conditions
tested in this study, CGTase is not excessively cytotoxic to cultured
TK6 cells and does not induce micronuclei in this test system. MN
frequency and cell viability data for cultures exposed to CGTase are
summarized in Table 2.
Sodium sulfate was  not toxic to cultured TK6 cells at the doses
tested. Precipitation was not observed at any tested dose. No pH
changes were noted based on media color change. Because the
induction of micronuclei was  less than 3-fold higher than the
vehicle control at all doses both with and without S9, the overall
response was  considered negative. These data indicate that, under
the test conditions used in this study, sodium sulfate is non-toxic
to cultured TK6 cells and does not induce micronuclei in this test
system. MN frequency and cell viability data for cultures exposed
to sodium sulfate are summarized in Table 2.
3.3. Results of the in vivo MN/Comet assays
Based on the results of preliminary dose setting studies, com-
bined MN/comet assays were conducted in which male and female
B6C3F1 mice were administered CGTase or sodium sulfate at 1000,
1500, and 2000 mg/kg/day for 3 consecutive days. No abnormal
clinical signs related to chemical administration were noted during
the course of the studies for CGTase, sodium sulfate, or the EMS  pos-
itive control. Following CGTase administration, a decreasing trend
in body weight gain without an effect in ﬁnal body weight was seen
in male mice but not regarded as biologically relevant. There was no
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Table 1
Bacterial reverse mutation assay for CGTase and sodium sulfate.
Dose (g/plate) Mean revertants/plate (± SD) without rat liver S9 Mean revertants/plate (± SD) with rat liver S9
TA97a TA100 TA98 TA1535 WP2  uvrA TA97a TA100 TA98 TA1535 WP2  uvrA
CGTase
0 103.0 ± 15.1 102.3 ± 7.0 20.7 ± 3.5 16.0 ± 2.6 134.3 ± 9.9 168.0 ± 17.1 99.0 ± 4.6 36.0 ± 3.6 13.3 ± 8.0 170.0 ± 8.2
25  123.0 ± 25.4 87.7 ± 4.9b 19.7 ± 4.2 17.7 ± 3.5 133.3 ± 10.3 155.7 ± 31.6 86.3 ± 1.2 36.0 ± 1.7 11.3 ± 3.5 136.3 ± 12.3
50  132.0 ± 6.2 79.3 ± 3.8 21.5 ± 4.9b 16.7 ± 1.5 115.7 ± 7.0 185.3 ± 6.8 101.0 ± 4.4 31.7 ± 7.4 14.3 ± 1.5 182.7 ± 26.4
75  137.5 ± 17.7b 86.3 ± 7.0 20.3 ± 4.0 10.7 ± 4.5 116.0 ± 24.6 177.0 ± 29.8 87.0 ± 6.0 36.0 ± 2.6 10.0 ± 3.6 168.0 ± 22.3
100  137.7 ± 9.1 85.0 ± 11.1 14.0 ± 5.3 10.7 ± 0.6 139.5 ± 20.5b 165.7 ± 11.5 107.0 ± 9.5 42.0 ± 5.6 13.3 ± 2.1 174.3 ± 11.8
200  138.0 ± 22.9 85.7 ± 3.2 23.0 ± 2.6 16.5 ± 0.7 142.5 ± 0.7 172.3 ± 23.9 97.3 ± 6.1 19.0 ± 0.0c 15.0 ± 4.6 192.0 ± 13.1
625  123.5 ± 2.1b 87.0 ± 5.7 15.7 ± 4.2 16.0 ± 2.0b 109.0 ± 8.5b 168.0 ± 14.8 90.0 ± 38.2 34.0 ± 9.9c 13.7 ± 3.1 119.3 ± 0.6
2000  121.0 ± 0.0c 92.0 ± 17.0 NAa NAa 99.0 ± 14.0 173.0 ± 0.0c NAa 21.0 ± 0.0c NAa 127.0 ± 5.0
5000  NAa NAa NAa NAa NAa NAa 101 ± 0.0c NAa NAa NAa
PC 600 ± 133.1 707.3 ± 31.2 843.0 ± 132.9 652.7 ± 29.6 1569.7 ± 194.6 2035.7 ± 222.5 781.3 ± 66.6 1116 ± 109.1 321 ± 19.5 1260.7 ± 286.4
Sodium  sulfate
0 104.0 ± 9.8 101.3 ± 8.5 25.0 ± 8.7 13.7 ± 3.1 139.3 ± 27.1 122.0 ± 8.2 98.0 ± 21.9 26.0 ± 6.2 10.7 ± 2.9 178.7 ± 20.1
250  117.3 ± 8.5 97.0 ± 24.1 24.3 ± 7.0 12.7 ± 1.5 137.7 ± 64.9 113.0 ± 20.1 109.3 ± 15.5 20.0 ± 10.4 9.7 ± 1.5 188.7 ± 13.6
500  105.3 ± 0.6 100.3 ± 9.0 25.3 ± 4.5 12.7 ± 1.5 132.3 ± 34.3 117.7 ± 18.2 97.3 ± 14.5 23.7 ± 6.1 10.7 ± 2.5 186.7 ± 19.9
1000  111.0 ± 6.6 97.0 ± 6.1 23.3 ± 5.1 17.0 ± 5.2 162.0 ± 13.5 138.0 ± 11.4 87.7 ± 4.2 26.7 ± 9.8 8.7 ± 2.3 160.3 ± 28.7
1500  100.0 ± 10.1 102.3 ± 11.0 26.7 ± 6.7 7.0 ± 1.7 129.7 ± 50.6 130.0 ± 13.0 92.0 ± 10.5 27.0 ± 7.8 8.0 ± 2.6 209.0 ± 10.5
2500  111.0 ± 9.5 94.3 ± 14.4 21.7 ± 5.0 11.3 ± 2.9 131.7 ± 26.9 126.0 ± 17.5 82.0 ± 6.1 30.0 ± 9.5 7.7 ± 0.6 174.7 ± 37.5
5000  94.0 ± 11.8 83.3 ± 4.6 19.7 ± 1.2 19.7 ± 9.3 136.3 ± 39.4 128.7 ± 12.4 97.7 ± 11.0 37.0 ± 6.2 11.7 ± 4 159.0 ± 33.0
PC  828.3 ± 147.3 681.7 ± 117.2 696.3 ± 229.5 447.7 ± 20.6 1698.3 ± 243.9 1831.0 ± 89.2 505.3 ± 20.6 1712.0 ± 269.4 291.3 ± 12.0 1017.0 ± 132.9
NA = not analyzable; PC = positive control.
a Not analyzable due to bacterial overgrowth. Test agent has high starch content.
b One replicate with bacterial overgrowth.
c Two replicates with bacterial overgrowth.
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Table 2
Summary of in vitro micronucleus assay results for CGTase and sodium sulfate.
Dose (g/mL) Micronucleus
frequency (%)
Apoptotic/necrotic
cells (%)
Relative survival
(%)
Dose (g/mL) Micronucleus
frequency (%)
Apoptotic/necrotic
cells (%)
Relative
survival (%)
Mean Fold change Mean Fold change Mean Fold change Mean Fold change
CGTase
4 h with S9 24 h without S9
0  0.84 ± 0.2 1.0 1.6 ± 0.1 1.0 100 0 0.61 ± 0.1 1.0 1.6 ± 0.1 1.0 100
1000  0.66 ± 0.1 0.8 3.5 ± 0.1 2.2 106 1000 0.66 ± 0.0 1.1 3.2 ± 0.2 2.1 101
2000  1.06 ± 0.5 1.3 3.9 ± 1.8 2.4 75 2000 0.63 ± 0.1 1.0 4.3 ± 0.9 2.8 89
3000  0.83 ± 0.3 1.0 4.8 ± 1.7 3.0 74 3000 0.61 ± 0.0 1.0 4.6 ± 0.4 3.0 82
4000  0.82 ± 0.2 1.0 8.2 ± 3.5 5.2 78 4000 0.66 ± 0.1 1.1 4.0 ± 0.3 2.6 72
5000  0.80 ± 0.2 0.9 6.1 ± 1.1 3.9 65 5000 0.82 ± 0.2 1.3 4.7 ± 0.7 3.1 73
6000  0.89 ± 0.2 1.1 6.0 ± 0.8 3.8 62 6000 0.68 ± 0.1 1.1 5.8 ± 1.5 3.8 73
CP  3.53 ± 0.1 4.2 6.0 ± 2.0 3.8 52 VIN 9.81 ± 1.4 20.6 4.2 ± 0.1 3.0 57
Sodium sulfate
4 h with S9 24 h without S9
0  0.93 ± 0.1 1.0 2.4 ± 0.2 1.0 100 0 0.76 ± 0.4 1.0 2.3 ± 0.4 1.0 100
20.6  0.93 ± 0.0 1.0 1.9 ± 0.1 0.8 103 20.6 0.56 ± 0.1 0.7 2.0 ± 0.2 0.9 105
61.7  0.84 ± 0.1 0.9 2.2 ± 0.3 0.9 103 61.7 0.57 ± 0.1 0.8 2.0 ± 0.1 0.9 112
185  0.78 ± 0.0 0.8 2.1 ± 0.2 0.9 106 185 0.54 ± 0.1 0.7 2.0 ± 0.2 0.9 98
556  1.01 ± 0.1 1.1 2.0 ± 0.2 0.8 101 556 0.58 ± 0.1 0.8 1.8 ± 0.3 0.8 104
1667  0.84 ± 0.0 0.9 2.0 ± 0.2 0.9 85 1667 0.57 ± 0.1 0.8 2.0 ± 0.2 0.9 87
5000  1.18 ± 0.0 1.3 2.8 ± 0.1 1.2 72 5000 0.53 ± 0.0 0.7 2.5 ± 0.3 1.1 86
CP  7.49 ± 1.1 7.6 10.6 ± 2.5 3.8 37 VIN 6.25 ± 0.7 13.0 7.4 ± 0.5 4.1 51
CP = cyclophosphamide; VIN = vinblastine.
Table 3
Summary of micronucleus assay results for CGTase and sodium sulfate.
Dose (mg/kg) Males Females
Mean% RET ± SEM Mean MN-RET/
1000 ± SEM
Mean M N-NCE/
1000 ± SEM
Mean% RET ± SEM Mean MN-RET/
1000 ± SEM
Mean M N-NCE/
1000 ± SEM
CGTase
0 1.5 ± 0.1 2.3 ± 0.2 1.4 ± 0.0 1.3 ± 0.1 2.4 ± 0.6 1.2 ± 0.0
1000  1.8 ± 0.2 2.4 ± 0.3 1.4 ± 0.0 1.3 ± 0.1 2.3 ± 0.2 1.2 ± 0.0
1500  1.6 ± 0.1 2.5 ± 0.3 1.4 ± 0.1 1.2 ± 0.1 2.4 ± 0.3 1.2 ± 0.0
2000  1.7 ± 0.1 2.4 ± 0.2 1.4 ± 0.0 1.1 ± 0.1 2.1 ± 0.2 1.1 ± 0.0
EMS  (150) 1.1 ± 0.1 10.8 ± 2.4* 1.4 ± 0.0 0.7 ± 0.1 16.1 ± 0.8* 1.2 ± 0.0
Sodium sulfate
0 1.4 ± 0.0 2.2 ± 0.3 1.4 ± 0.0 1.3 ± 0.1 2.5 ± 0.3 1.2 ± 0.1
1000  1.4 ± 0.0 2.2 ± 0.2 1.4 ± 0.0 1.1 ± 0.1 2.0 ± 0.1 1.2 ± 0.0
1500  1.6 ± 0.1 2.4 ± 0.1 1.4 ± 0.0 1.5 ± 0.1 2.2 ± 0.2 1.1 ± 0.0
2000  1.7 ± 0.2 2.3 ± 0.1 1.5 ± 0.0 1.1 ± 0.2 2.2 ± 0.2 1.2 ± 0.0
EMS  (150) 1.1 ± 0.1 9.6 ± 1.7* 1.5 ± 0.0 0.9 ± 0.1 8.8 ± 0.4* 1.2 ± 0.0
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cEM = standard error of the mean EMS  = ethyl methanesulfonate.
* p < 0.05.
uggestion of bone marrow toxicity in mice administered CGTase
p to 2000 mg/kg/day as reﬂected by the lack of an effect on RET fre-
uency. The MN-RET frequency in mice administered CGTase was
ot signiﬁcantly different from concurrent vehicle controls; there-
ore, the MN  assay was clearly negative in both male and female
ice. Results for the MN  assay of CGTase are summarized in Table 3.
Induction of DNA damage was not observed in liver, duodenum,
r stomach of male or female mice exposed to CGTase. Moreover,
here was no associated dose-related trend and the data for the
GTase (and vehicle control) dose groups were within the 95%
onﬁdence interval of laboratory historical vehicle control data.
herefore, the comet assay conducted in mice is considered neg-
tive. Comet assay results for CGTase are presented in Table 4.
In mice administered sodium sulfate there were no signiﬁcant
hanges in ﬁnal body weight with slight, statistically signiﬁ-
ant increases in body weight gain in males administered 1000
r 2000 mg/kg/day and females administered 2000 mg/kg/day
odium sulfate compared to concurrent controls. No adverse clini-
al observations were noted during the course of the study. MN-RET
requency and DNA damage were not signiﬁcantly different from
oncurrent controls as tested via the MN  assay and comet assay,respectively. MN and comet assay results for sodium sulfate are
summarized in Tables 3 and 4, respectively.
For both CGTase and sodium sulfate studies, administration of
EMS, the positive control, to male and female mice resulted in a
signiﬁcant increase in MN frequency in peripheral blood and an
increase in% tail DNA for liver, stomach, and duodenum when com-
pared to the concurrent controls.
3.4. Results for the 90-day study
3.4.1. Dose formulation and analysis
Formulation analysis for concentration, uniformity, and homo-
geneity performed monthly were generally greater than theoretical
concentrations with minor exceptions involving low or mid-dose
formulations (data not shown). These exceptions did not negatively
impact the study or affect the ability to establish a NOAEL.3.4.2. Mortality/moribundity and clinical observations
Two males did not survive to study termination. One in the
250 mg/kg/day CGTase group died immediately following gavage
of the 62nd dose administration and one in the 500 mg/kg/day
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Table  4
Summary of comet assay results for CGTase and sodium sulfate.
Males Females
% Tail DNA (Mean ± SEM) % Tail DNA (Mean ± SEM)
Dose (mg/kg) Liver Duodenum Stomach Liver Duodenum Stomach
CGTase
0 5.6 ± 0.6 5.9 ± 0.8 11.2 ± 0.7 3.8 ± 0.8 4.5 ± 1.1 6.6 ± 1.8
1000  5.6 ± 0.5 5.2 ± 0.5 9.0 ± 1.14 3.5 ± 0.7 4.5 ± 0.8 6.6 ± 1.8
1500  5.9 ± 0.5 4.6 ± 0.5 11.7 ± 3.81 4.9 ± 0.4 3.5 ± 0.6 6.1 ± 1.7
2000  6.8 ± 0.4 4.6 ± 0.6 12.2 ± 2.31 4.5 ± 0.8 3.1 ± 0.5 7.9 ± 2.1
EMS  (150) 15.4 ± 1.0* 10.2 ± 0.9* 16.5 ± 1.25* 16.7 ± 2.3* 11.1 ± 0.8* 10.5 ± 1.0*
Sodium sulfate
0 3.2 ± 0.5 3.7 ± 0.6 6.1 ± 0.9 8.4 ± 4.1 10.6 ± 1.4 3.2 ± 0.4
1000  2.9 ± 0.5 3.5 ± 0.5 3.7 ± 0.8 4.1 ± 1.0 7.8 ± 1.0 2.6 ± 0.2
1500  4.2 ± 0.5 2.7 ± 0.2 6.3 ± 1.5 4.1 ± 0.7 8.1 ± 2.0 3.1 ± 0.3
2000  3.1 ± 0.5 3.3 ± 0.5 3.7 ± 0.8 4.2 ± 0.3 11.7 ± 2.4 2.6 ± 0.2
EMS  (150) 13.9 ± 1.0* 9.4 ± 1.2* 18.3 ± 2.7* 13.5 ± 1.9* 16.2 ± 2.4* 10.1 ± 1.4*
SEM = standard error of the mean; EMS  = ethyl methanesulfonate.
* p < 0.05.
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roup was euthanized for humane reasons following 87 days of
GTase administration. Macroscopic evaluation attributed these
arly deaths to gavage error. Tissue weights and clinical pathology
ata collected from the euthanized rat were not used in statistical
nalyses. No abnormal cage-side clinical abnormalities attributed
o CGTase were observed during the course of the study. Mild
orneal crystals in four rats (one male and three females) were
bserved prior to initiation of dose administration and in one addi-
ional rat (control male) a week before study termination.
.4.3. Body weight and food consumption
Mean initial and ﬁnal body weight and body weight gain follow-
ng 90 consecutive days of CGTase administration are presented in
ig. 2. There were no signiﬁcant changes in ﬁnal body weight or
ody weight gain in rats given CGTase when compared to concur-
ent controls. Likewise there were no signiﬁcant changes in mean
eed consumption in CGTase treated rats versus concurrent controls
Fig. 2).
.4.4. Neurotoxicity screening
Automated motor activity assessments following 80–82 days ofosing showed no signiﬁcant changes in rats administered CGTase
ersus concurrent controls (Fig. 3). Functional observations made
lind to treatment (e.g., home cage behavior, handling reactiv-
ty, visual and tactile responses, air righting, limb grip strength,mption in rats exposed to CGTase for 90 days.
hindlimb splay, etc.) identiﬁed very few alterations (data not
shown). The only statistically signiﬁcant effect of dose was  in
landing hindlimb splay in females administered 1000 mg/kg/day
CGTase. Hindlimb splay is a measure of a response that requires
proprioception and muscle strength. Since no similar changes were
seen in any of the other assessments that involve these modali-
ties, such as gait, righting, and extensor thrust, this effect in the
1000 mg/kg/day CGTase female is unlikely to be biologically signif-
icant. Furthermore, sciatic nerves were histopathologically normal
during subsequent microscopic evaluation. Based on these ﬁnd-
ings, administration of CGTase at up to 1000 mg/kg/day is unlikely
to present a neurotoxicity hazard based on OECD neurotoxicity
guidelines [16].
3.4.5. Urinalysis
Following an 18-hour urine collection, there were no signiﬁcant
pairwise changes in speciﬁc gravity, bilirubin, ketones, blood, pH,
protein, total volume, glucose, urobilinogen, sodium, and potas-
sium in male or female rats administered CGTase as compared
to the concurrent control groups. There was a statistically sig-
niﬁcant increasing trend in speciﬁc gravity and urine potassium
levels in female rats. Mean speciﬁc gravity values for females
were 1.011 ± 0.004, 1.014 ± 0.003, 1.015 ± 0.004, and 1.015 ± 0.004
speciﬁc gravity units for control, low-dose, mid-dose, and high-
dose rats, respectively. Mean female potassium milliequivalents/L
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Fig. 3. Motor activity in rats measured in 5-minute intervals over the course of one hour.
Table 5a
Hemogram data from rats exposed to CGTase for 90 days.
Dose level
(mg/kg/day)
Sex WBC  (1000/L)
± SD
RBC
(1000000/L) ± SD
HGB (g/dL) ± SD HCT (%) ± SD MCV  (Fl) ± SD MCH  (pg) ± SD MCHC (g/dL) ± SD
0 M 12.69 ± 2.60 (10)a 10.37 ± 0.90 (10) 21.7 ± 1.7 (10) 60.4 ± 6.0 (10) 58.1 ± 1.3 (10) 21.0 ± 0.9 (10) 36.1 ± 1.5 (10)
250  M 12.22 ± 2.57 (8) 9.88 ± 0.62 (8) 21.0 ± 1.3 (8) 57.5 ± 2.9 (8) 58.3 ± 1.7 (8) 21.3 ± 1.0 (8) 36.4 ± 0.8 (8)
500  M 13.71 ± 2.49 (6) 9.92 ± 0.34 (6) 20.6 ± 1.1 (6) 57.4 ± 3.5 (6) 57.8 ± 2.1 (6) 20. 8 ± 0.6 (6) 36.0 ± 0.9 (6)
1000  M 12.15 ± 2.06 (9) 9.49 ± 0.46* (9) 20.0 ±0.7* (9) 54.9 ± 2.9* (9) 57.9 ± 1.7 (9) 21.1 ± 0.6 (9) 36.4 ± 1.2 (9)
0  F 9.24 ± 3.21 (9) 9.05 ± 0.85 (9) 20.2 ± 1.5 (9) 53.2 ± 5.3 (9) 58.7 ± 1.0 (9) 22.3 ± 0.7 (9) 38.0 ± 1.3 (9)
250  F 9.16 ± 0.83 (8) 8.94 ± 0.48 (8) 19.6 ± 0.6 (8) 52.0 ± 2.8 (8) 58.2 ± 1.4 (8) 21.9 ± 0.7 (8) 37.6 ± 1.4 (8)
500  F 8.80 ± 1.82 (10) 9.27 ± 0.48 (10) 20.1 ± 1.3 (10) 54.1 ± 3.4 (10) 58.4 ± 1.2 (10) 21.7 ± 1.0 (10) 37.2 ± 1.4 (10)
1000  F 9.72 ± 2.46 (9) 9.36 ± 0.60 (9) 20.0 ± 0.9 (9) 54.4 ± 3.2 (9) 58.1 ± 1.0 (9) 21.4 ± 0.8* (9) 36.7 ± 1.2 (9)
SD = standard deviation; WBC  = white blood cells; RBC = red blood cells; HGB = hemoglobin; HCT = hematocrit; MCV  = mean corpuscular volume; MCH  = mean corpuscular
hemoglobin; MCHC = mean corpuscular hemoglobin concentration.
a Number of samples.
* Statistically signiﬁcant when compared to the concurrent control, p < 0.05.
Table 5b
Platelet and absolute white blood cell differential counts from rats exposed to CGTase for 90 days.
Dose Level
(mg/kg/day)
Sex Platelets
(1000/L) ± SD
Lymphocytes
(1000/L) ± SD
Monocytes
(1000/L) ± SD
Eosinophils
(1000/L) ± SD
Basophils
(1000/L) ± SD
Leukocytes
(1000/L) ± SD
Neutrophils
(1000/L) ± SD
0 M 720 ± 210 (10)a 10.35 ± 2.11 (10) 0.42 ± 0.15 (10) 0.16 ± 0.06 (10) 0.23 ± 0.13 (10) 0.14 ± 0.04 (10) 1.41 ± 0.28 (10)
250  M 754 ± 211 (8) 9.58 ± 2.29 (8) 0.39 ± 0.14 (8) 0.32 ± 0.35 (8) 0.17 ± 0.06 (8) 0.12 ± 0.05 (8) 1.65 ± 0.36 (8)
500  M 771 ± 178 (6) 10.60 ± 2.02 (6) 0.44 ± 0.10 (6) 0.21 ± 0.11 (6) 0.19 ± 0.04 (6) 0.13 ± 0.05 (6) 2.14 ± 0.73* (6)
1000  M 818 ± 122 (9) 9.81 ± 1.79 (9) 0.41 ± 0.11 (9) 0.19 ± 0.10 (9) 0.15 ± 0.06 (9) 0.15 ± 0.04 (9) 1.44 ± 0.29 (9)
0  F 804 ± 273 (9) 7.45 ± 2.99 (9) 0.28 ± 0.10 (9) 0.20 ± 0.17 (9) 0.13 ± 0.08 (9) 0.10 ± 0.05 (9) 1.08 ± 0.31 (9)
250  F 858 ± 104 (8) 7.56 ± 0.62 (8) 0.26 ± 0.06 (8) 0.15 ± 0.08 (8) 0.11 ± 0.02 (8) 0.11 ± 0.02 (8) 0.97 ± 0.32 (8)
500  F 885 ± 163 (10) 7.36 ± 1.77 (10) 0.32 ± 0.14 (10) 0.14 ± 0.07 (10) 0.10 ± 0.04 (10) 0.09 ± 0.04 (10) 1.09 ± 0.34 (10)
1000  F 686 ± 210 (9) 7.76 ± 2.19 (9) 0.34 ± 0.17 (9) 0.22 ± 0.16 (9) 0.12 ± 0.05 (9) 0.12 ± 0.06 (9) 1.18 ± 0.28 (9)
SD = Standard deviation.
a Number of samples.
* Statistically signiﬁcant when compared to the concurrent control, p < 0.05.
Table 5c
Relative White Blood Cell Differential Counts from Rats Exposed to CGTase for 90 days.
Dose Level (mg/kg/day) Sex Lymphocytes% ± SD Monocytes% ± SD Eosinophils% ± SD Basophils % ± SD Leukocytes% ± SD Neutrophils% ± SD
0.0 M 81.6 ± 1.5 (10)a 3.2 ± 0.7 (10) 1.2 ± 0.4 (10) 1.7 ± 0.7 (10) 1.1 ± 0.2 (10) 11.2 ± 1.7 (10)
250  M 78.1 ± 5.7 (8) 3.1 ± 0.7 (8) 2.7 ± 3.3 (8) 1.4 ± 0.3 (8) 0.9 ± 0.3 (8) 13.7 ± 3.3 (8)
500  M 77.3 ± 4.0 (6) 3.2 ± 0.6 (6) 1.5 ± 0.6 (6) 1.4 ± 0.1 (6) 1.0 ± 0.3 (6) 15.7 ± 4.6 (6)
1000  M 80.6 ± 2.2 (9) 3.3 ± 0.7 (9) 1.6 ± 0.6 (9) 1.2 ± 0.3 (9) 1.2 ± 0.3 (9) 12.0± 2.6 (9)
0.0  F 79.8 ± 4.8 (9) 3.2 ± 0.9 (9) 2.3 ± 2.0 (9) 1.4 ± 0.3 (9) 1.0 ± 0.3 (9) 12.3 ± 3.7 (9)
250  F 82.7 ± 3.3 (8) 2.9 ± 0.7 (8) 1.6 ± 0.9 (8) 1.3 ± 0.2 (8) 1.2 ± 0.2 (8) 10.4 ± 2.8 (8)
500  F 79.9 ±4.9 (10) 3.6 ± 0.1 (10) 1.6 ± 0.7 (10) 1.2 ± 0.2 (10) 1.0 ± 0.4 (10) 12.8 ± 4.1 (10)
1000  F 79.3 ± 4.5 (9) 3.4 ± 0.1 (9) 2.3 ± 0.2 (9) 1.2 ± 0.2 (9) 0.1 ± 0.1 (9) 12.7 ± 4.3 (9)
S
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ere 35.3 ± 15.1, 43.2 ± 15.1, 50.7 ± 15.7 and 50.0 ± 17.7 for con-
rol, low-dose, mid-dose, and high-dose rats, respectively. No other
igniﬁcant dose-dependent trends were measured. The signiﬁcance
f these two trends in female rats is unknown.3.4.6. Hematology
Hemogram data are presented in Tables 5a–5c. The low platelet
count in high-dose females was  not statistically different from
the control group and was  within the laboratory reference range
for this rat strain and age. There was  a statistically signiﬁcant
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Table 6a
Clinical chemistry analyte data from rats exposed to CGTase for 90 days.
Dose Level (mg/kg/day) Sex Na+
(mmol/L) ± SD
K+ (mmol/L) ± SD Cl−(mmol/L) ± SD Calcium
(mg/dL) ± SD
Phosphorous
(mg/dL) ± SD
AST (/L) ± SD ALT (/L) ± SD ALP (/L) ± SD GGT (/L) ± SD Glucose
(mg/dL) ± SD
0 M 156 ± 6 (10)a 11.0 ± 1.1 (10) 105 ± 4 (10) 13.2 ± 0.9 (10) 13.9 ± 0.8 (10) 97 ± 13 (10) 44 ± 5 (10) 123 ± 28 (10) 0 ± 0 (10) 236 ± 81 (10)
250  M 158 ± 5 (9) 10.5 ± 1.4 (9) 106 ± 3 (9) 13.0 ± 0.6 (9) 13.8 ± 1.1 (9) 95 ± 8 (9) 41 ± 4 (9) 130 ± 19 (9) 0 ± 0 (9) 249 ± 44 (9)
500  M 156 ± 4 (10) 10.5 ± 0.9 (10) 106 ± 6 (10) 13.1 ± 1.1 (10) 14.2 ± 1.1 (10) 106 ± 33 (10) 48 ± 26 (10) 130 ± 30 (10) 0 ± 0 (10) 255 ± 78 (10)
1000  M 160 ± 5 (10) 10.7 ± 0.9 (10) 107 ± 3 (10) 13.4 ± 0.8 (10) 14.3 ± 0.5 (10) 102 ± 11 (10) 47 ± 11 (10) 130 ± 18 (10) 0 ± 0 (10) 306 ± 53 (10)
0  F 154 ± 9 (10) 11.5 ± 1.4 (10) 109 ± 5 (10) 12.7 ± 1.1 (10) 13.8 ± 1.5 (10) 107 ± 14 (10) 36 ± 4 (10) 87 ± 18 (10) 0 ± 0 (10) 120 ± 25 (10)
250  F 152 ± 8 (10) 12.4 ± 1.8 (10) 108 ± 5 (10) 12.7 ± 1.1 (10) 14.5 ± 1.7 (10) 125 ± 45 (10) 46 ± 15 (10) 92 ± 19 (10) 0 ± 0 (10) 136 ± 58 (10)
500  F 158 ± 10 (10) 11.2 ± 1.1 (10) 110 ± 6 (10) 13.3 ± 0.9 (10) 14.8 ± 0.9 (10) 113 ± 20 (10) 40 ± 7 (10) 95 ± 17 (10) 0 ± 0 (10) 157 ± 34 (10)
1000  F 153 ± 5 (10) 12.5 ± 1.5 (10) 108 ± 2 (10) 12.9 ± 0.6 (10) 14.1 ± 0.7 (10) 103 ± 16 (10) 37 ± 10 (10) 104 ± 22 (10) 0 ± 0 (10) 193 ± 72* (10)
AST = aspartate aminotransferase ALT = alanine aminotransferase ALP = alkaline phosphatase GGT = gamma glutamyltransferase.
SD—standard deviation.
a Number of samples.
* Statistically signiﬁcant when compared to the concurrent control, p < 0.05.
Table 6b
Clinical Chemistry Analyte Data for Rats Exposed to CGTase for 90 days.
Dose Level
(mg/kg/day)
Sex BUN (mg/dL) ±
SD
Creatinine
(mg/dL) ± SD
Cholesterol
(mg/dL) ± SD
Triglyceride
(mg/dL) ± SD
Total Bilirubin
(mg/dL) ± SD
Sorbitol
Dehydrogenase
(/L) ± SD
Total Protein
(g/dL) ± SD
Albumin (g/dL) ±
SD
Globulin (g/dL) ±
SD
Bile Acids
(MOL/L) ± SD
0 M 18 ± 2 (10)a 0.7 ± 0.1 (10) 108 ± 18 (10) 65 ± 10 (10) 0.1 ± 0.1 (10) 29.5 ± 10.8 (10) 7.8 ± 0.6 (10) 3.8 ± 0.2 (10) 4.0 ± 0.5 (10) 32.1 ± 29.1 (10)
250  M 18 ± 2 (9) 0.6 ± 0.1 (9) 105 ± 17 (9) 60 ± 11 (9) 0.2 ± 0.1 (9) 32.4 ± 8.4 (9) 7.8 ± 0.4 (9) 3.8 ± 0.2 (9) 3.9 ± 0.3 (9) 26.1 ± 17.2 (9)
500  M 18 ± 2 (10) 0.6 ± 0.1 (9) 101 ± 25 (10) 62 ± 8 (10) 0.2 ± 0.1 (10) 27.5 ± 6.3 (10) 7.6 ± 0.7 (10) 3.7 ± 0.4 (10) 3.9 ± 0.4 (10) 20.3 ± 12.2 (10)
1000  M 20 ± 3 (10) 0.6 ± 0.1 (10) 102 ± 9 (10) 63 ± 12 (10) 0.2 ± 0.1 (10) 32.7 ± 9.8 (10) 8.0 ± 0.4 (10) 3.9 ± 0.2 (10) 4.0 ± 0.2 (10) 33.2 ± 26.8 (10)
0  F 19 ± 3 (10) 0.7 ± 0.1 (10) 99 ± 20 (10) 57 ± 13 (10) 0.2 ± 0.0 (10) 35.3 ± 8.4 (10) 7.6 ± 0.7 (10) 3.9 ± 0.3 (10) 3.7 ± 0.4 (10) 75.9 ± 155.7 (10)
250  F 20 ± 2 (10) 0.7 ± 0.1 (10) 96 ± 21 (10) 53 ± 14 (10) 0.2 ± 0.0 (10) 31.9 ± 5.1 (10) 7.7 ± 0.6 (10) 4.0 ± 0.3 (10) 3.7 ± 0.3 (10) 44.3 ± 33.6 (10)
500  F 19 ± 2 (10) 0.7 ± 0.1 (10) 103 ± 27 (10) 52 ± 9 (10) 0.2 ± 0.0 (10) 31.7 ± 6.8 (10) 8.0 ± 0.7 (10) 4.1 ± 0.3 (10) 4.0 ± 0.4 (10) 34.7 ± 21.9 (10)
1000  F 18 ± 1 (10) 0.6 ± 0.1 (10) 103 ± 24 (10) 52 ± 12 (10) 0.2 ± 0.0 (10) 25.8 ± 8.0* (10) 7.8 ± 0.6 (10) 3.9 ± 0.2 (10) 3.9 ± 0.4 (10) 45.8 ± 42.8 (10)
SD = standard deviation; BUN = blood urea nitrogen.
*Statistically signiﬁcant when compared to the concurrent control, p < 0.05.
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Table 7
Coagulation tests and hormone analyses.
Dose level (mg/kg/day) Sex PT (seconds) ± SD APTT (seconds) ± SD Total T3 (ng/dL) ± SD Total T4 (g/dL) ± SD Total TSH (ng/mL) ± SD
0 M 11.9 ± 0.7 (10)a 21.9 ± 3.9 (10) 136.7 ± 38.9 (10) 4.5 ± 1.3 (10) 14.7 ± 8.7 (10.0)
250  M 12.0 ± 1.2 (9) 20.6 ± 2.9 (9) 117.9 ± 23.7 (9) 4.4 ± 0.8 (9) 15.7 ± 5.5 (9)
500  M 12.0 ± 0.8 (8) 21.4 ± 3.3 (8) 110.2 ± 28.3 (10) 3.9 ± 1.0 (10) 15.8 ± 5.4 (10)
1000  M 11.4 ± 0.6 (10) 21.2 ± 4.5 (10) 105.8 ± 21.9* (10) 3.7 ± 0.7 (10) 13.8 ± 4.2 (10)
0  F 11.0 ± 1.0 (10) 19.7 ± 3.4 (10) 108 ± 22.4 (10) 3.7 ± 0.9 (10) 10.9 ± 2.4 (10)
250  F 10.5 ± 0.3 (9) 18.9 ± 2.4 (9) 108.5 ± 19.1 (10) 4.2 ± 2.6 (10) 11.5 ± 2.3 (10)
500  F 10.6 ± 0.6 (10) 19.0 ± 2.4 (10) 133.9 ± 25.1* (10) 4.2 ± 0.6 (10) 12.8 ± 2.9 (10)
1000  F 10.6 ± 1.0 (10) 18.6 ± 2.3 (10) 
SD = standard deviation; PT = prothrombin time; APTT = activated partial throm-
boplastin time; T3 = triiodothyronine; T4 = thyroxine; TSH = thyroid stimulating
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* Statistically signiﬁcant when compared to the concurrent control, p < 0.05.
ecrease in red blood cells (92% of control), hemoglobin (92% of
ontrol), and hematocrit (91% of control) in male rats administered
000 mg/kg/day CGTase as compared to the concurrent controls;
here was a signiﬁcant increase in % neutrophils (139% of controls)
nd absolute neutrophils (152% of controls) in males administered
00 mg/kg/day CGTase compared to the concurrent control group
ith a signiﬁcant corresponding increasing trend. There was a sig-
iﬁcant decreasing trend in percent lymphocytes in males without
ny statistically signiﬁcant associated decreases in any of the male
ose groups. MCH  (97% of control) was statistically decreased in
emale rats administered 1000 mg/kg/day CGTase compared to the
oncurrent control group. Signiﬁcant changes in hemogram results
ere within the performing laboratory reference range with the
xception of elevated hemoglobin in males that was slightly above
he laboratory reference range. There were no microscopic corre-
ates related to the statistically signiﬁcant hemogram effects.
.4.7. Serum clinical chemistry
Clinical chemistry analyte data are presented in
ables 6a and 6b. A signiﬁcant increase in glucose (162% of
ontrol) and a signiﬁcant decrease in sorbitol dehydrogenase
SDH; 73% of control) were measured in female rats administered
000 mg/kg/day CGTase compared to the concurrent controls.
he signiﬁcantly decreased SDH result was within the performing
aboratory reference range whereas the elevated glucose level was
bove the reference range. The increased glucose concentration
ay  be a result of the administration of the test article containing
6% carbohydrates. There was no effect of CGTase administration
n glucose or SDH levels in male rats. There were no histopatho-
ogical changes that correlate with the observed serum chemistry
hanges.
.4.8. Coagulation and hormone analyses
Prothrombin, activated partial thromboplastin times, thyroxine
T4) and thyroid stimulating hormone (TSH) were not signiﬁ-
antly changed for either gender compared to concurrent controls
Table 7). Serum triiodothyronine (T3) levels were signiﬁcantly
ecreased in male rats administered 1000 mg/kg/day CGTase (77%
f control) and signiﬁcantly increased in female rats adminis-
ered 500 or 1000 mg/kg/day CGTase (124% and 129%, respectively).
erum T3 levels in female rats exhibited a signiﬁcant dose-
ependent decrease. Serum T3 values for male and female rats were
utside the performing laboratory reference range. There were no
icroscopic ﬁndings in the thyroid or other endocrine organs that
eﬂected the changes in serum T3 values..4.9. Macroscopic ﬁndings and tissue weights
There were no macroscopic ﬁndings at necropsy or changes in
issue weights that were related to CGTase exposure.139.9 ± 24.2* (10) 4.2 ± 0.8 (10) 11.3 ± 2.5 (10)
3.4.10. Histopathology
Histopathological ﬁndings from high-dose and control male
and females reﬂect common incidental background lesions seen
in Sprague Dawley rats of this age with incidences listed in Table 8.
Observations that correlate with macroscopic observations include
colonic lymphoid hyperplasia (250 mg/kg/day male), decreased
secretion in seminal vesicles (500 mg/kg/day male), splenic ectopia
in the mesentery (500 mg/kg/day male), lymph node lymphoid
hyperplasia and plasmacytosis (500 mg/kg/day male), hepatodi-
aphragmatic nodule and lymph node congestion (500 mg/kg/day
female).
4. Discussion
CGTase, a natural microbial enzyme produced by Bacillus pseu-
doalcaliphilus DK-1139, can be used to efﬁciently glycosylate
molecules such as isoquercitrin to produce an enzyme modiﬁed
product for use as a food ingredient. Even though CGTase is heat
inactivated and not present in the ﬁnal product generated from its
use, international guidelines call for safety assessment of microbial
derived human and animal food products and additives [6,7]. Based
on results of dose range-ﬁnding studies, we  used a high limit dose
of 2000 and 1000 mg/kg/day in 3-day micronucleus/comet and 90-
day toxicity studies, respectively, in accordance with regulatory
testing guidelines for non-toxic materials [19]. We  conducted a bat-
tery of in vitro and in vivo genotoxicity assays and a 90-day repeated
dose gavage study in Sprague Dawley rats with no evidence of
genotoxicity or systemic toxicity using CGTase from Bacillus pseu-
doalcaliphilus DK-1139. We  also report negative genotoxicity for
sodium sulfate that is present at low levels in preparations of
CGTase.
Much contemporary research is focused on the genetic under-
pinnings related to the biological role as well as production and
applications of CGTases including use of recombinant DNA  tech-
nology to modify natural microbial enzymes for speciﬁc food
processing needs [23,21,12,11,9]. We identiﬁed one safety evalua-
tion of a CGTase from a recombinant bacterial strain with results
similar to our study [4]. In that study there was no evidence of
genotoxicity and the only systemic effects were non-dose-related
pulmonary irritation secondary to reﬂux of the gavaged test mate-
rial. The authors concluded that their CGTase was  safe for the
intended use in production of alpha-cyclodextrin.
How much, if any, of the orally administered CGTase was
absorbed in the present study is unknown. Negative results of our
GLP genotoxicity battery on CGTase and sodium sulfate and lack of
adverse toxicity in rats exposed to a limit dose of 1000 mg/kg/day
for 90 days support the safe use of CGTase in the production of
alpha-glycosyl isoquercitrin.Acknowledgements
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Table  8
Incidental microscopic ﬁndings in rats exposed to CGTase for 90 days.
Dose level
Males Females
0 mg/kg 1000 mg/kg 0 mg/kg 1000 mg/kg
Nasal cavity
Olfactory epithelium, degeneration 1/10 0/10 0/10 0/10
Olfactory epithelium, atrophy 1/10 0/10 0/10 0/10
Turbinate, accumulation, eosinophilic 1/10 0/10 0/10 0/10
Clitoral glands
Inﬂammation, mixed 0/10 0/10 0/10 1/10
Dilation, glandular 0/10 0/10 0/10 1/10
Esophagus
Inﬂammation, granulomatous 0/10 0/10 0/10 1/10
Muscularis, degeneration 0/10 0/10 0/10 1/10
Heart
Cardiomyopathy, progressive 2/10 4/10 0/10 0/10
Kidneys
Cast,  hyaline, unilateral 0/10 0/10 1/10 1/10
Chronic progressive nephropathy, bilateral 9/10 8/10 1/10 2/10
Chronic progressive nephropathy, unilateral 1/10 1/10 3/10 2/10
Mineralization, unilateral 0/10 0/10 0/10 1/10
Accumulation, hyaline, bilateral 1/10 0/10 0/10 0/10
Accumulation, hyaline, unilateral 1/10 0/10 0/10 1/10
Liver
Inﬁltration, mixed 1/10 1/10 0/10 2/10
Vacuolation, hepatocellular 0/10 0/10 0/10 1/10
Capsule, hypercellularity 0/10 0/10 0/10 1/10
Lung
Alveolus, histiocytosis 0/10 1/10 0/10 0/10
Inﬁltration, mixed 1/10 1/10 1/10 1/10
Inﬂammation, mixed 0/10 0/10 0/10 1/10
Lymph node, mediastinal
Angiectasis 1/10 0/10 0/10 0/10
Lymph node, mesenteric
Congestion 0/10 1/10 0/10 0/10
Lymph node, mandibular
Cyst 1/10 0/10 0/10 0/10
Pancreas
Ectopia, spleen 0/10 1/10 0/10 0/10
Pituitary
Pars  distalis, hyperplasia 1/10 0/10 0/10 0/10
Rathkes cleft, dilation 0/10 1/10 0/10 1/10
Spleen
Fibrosis, capsular 0/10 1/10 0/10 0/10
Thyroid/parathyroid
Cyst,  unilateral 2/10 0/10 0/10 1/10
Ectopia 0/10 1/10 0/10 0/10
Trachea
Dilation, glandular 3/10 1/10 1/10 3/10
Ulceration, epithelial 1/10 0/10 0/10 0/10
Uterus
Lumen, dilation, unilateral 0/10 0/10 0/10 1/10
Endometrium, hyperplasia, cystic 0/10 0/10 1/10 0/10
F
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TVagina
Submucosa, inﬁltration, mixed 0/10 
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